Zealand Pharma has partnered with Generate Biomedicines to develop protein based treatments for obesity and other metabolic diseases designed with Generate’s artificial intelligence platform. Generate receives $30 million upfront and up to $35 million in early preclinical milestones, and is eligible for total milestone payments of nearly $1.2 billion. Generate shares rose about 5 percent in extended trading on the announcement.
The work is aimed past the current GLP-1 generation. The collaboration will focus on multispecific protein therapies, single medicines designed to act on more than one biological pathway linked to obesity at once. Generate, a Flagship Pioneering company that went public earlier this year, will lead research through candidate selection. Zealand takes over clinical development, regulatory filings and worldwide commercialization for anything that emerges.
For Zealand the deal is a second front. The Danish company has built its obesity position on peptides, and is jointly developing petrelintide with Roche under an agreement worth up to $5.3 billion signed last year. Earlier this month Zealand reported mid stage results in which petrelintide helped patients with type 2 diabetes lose up to 9.2 percent of body weight. Adding AI designed proteins gives Zealand a discovery engine in a modality it does not build internally, at the cost of an upfront payment that is small against the milestone tail.
The structure is the standard 2026 obesity pattern: modest cash now, a large contingent number later, and the real value decided by whether any designed protein survives first in human testing. With Novo Nordisk and Eli Lilly setting the efficacy bar and dozens of followers competing on convenience and tolerability, multispecific designs are one of the few remaining claims to a step change rather than an incremental gain.